Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

Documenti analoghi

• Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
  di: Hall, Stephen, et al.
  Pubblicazione: (2018)
• Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
  di: Cohen, Stanley B, et al.
  Pubblicazione: (2017)
• The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
  di: Winthrop, Kevin L, et al.
  Pubblicazione: (2016)
• Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
  di: Jürgen Wollenhaupt, et al.
  Pubblicazione: (2019-04-01)
• Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
  di: Wollenhaupt, Jürgen, et al.
  Pubblicazione: (2019)